Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshihiro Oka

Showing results (1-10 of 132) with videos related to

Pageof 14
Sort By:
Nihon Rinsho Men'Eki Gakkai Kaishi = Japanese Journal of Clinical Immunology|November 1, 2008
[Cancer antigen WT1-targeting treatment for the malignancies]Yoshihiro Oka, Ichiro Kawase
Immunotherapy|September 30, 2010
WT1 peptide vaccine, one of the most promising cancer vaccines: its present status and the future prospectsYoshihiro Oka, Haruo Sugiyama
Tanpakushitsu Kakusan Koso. Protein, Nucleic Acid, Enzyme|August 23, 2003
[Cancer immunotherapy targeting WT1 product which overexpressess in various kinds of malignant neoplasms]Yoshihiro Oka, Akihiro Tsuboi, Haruo Sugiyama
Expert Review of Hematology|March 19, 2019
What should we tackle next in acute myeloid leukemia? Wilms tumor gene 1 vaccine therapy would be a promising and versatile strategy for acute myeloid leukemiaJun Nakata, Yusuke Oji, Yoshihiro Oka, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|September 17, 2002
[Cellular and humoral immune responses against WT1 products overexpressed in hematopoietic malignancies]Yoshihiro Oka, Akihiro Tsuboi, Yusuke Oji, et al.
Current Opinion in Immunology|May 27, 2008
WT1 peptide vaccine for the treatment of cancerYoshihiro Oka, Akihiro Tsuboi, Yusuke Oji, et al.
Materials (Basel, Switzerland)|January 21, 2023
Dispersion of Long and Isolated Single-Wall Carbon Nanotubes by Using a Hydrodynamic Cavitation MethodShunjiro Fujii, Shin-Ichi Honda, Yoshihiro Oka, et al.
Haematologica|March 17, 2004
Allogeneic bone marrow transplantation with non-T-cell-depleted marrow from two HLA-antigen-mismatched related donorsHiroyasu Ogawa, Kazuhiro Ikegame, Manabu Kawakami, et al.
Pediatric Blood & Cancer|June 29, 2010
WT1 peptide immunotherapy for cancer in children and young adultsYoshiko Hashii, Emiko Sato, Hideaki Ohta, et al.
Brain and Nerve = Shinkei Kenkyu No Shinpo|July 22, 2009
[Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors]Naoya Hashimoto, Akihiro Tsuboi, Yasuyoshi Chiba, et al.
Pageof 14

Showing results (1-10 of 132) with videos related to

Sort By:
Pageof 14
Nihon Rinsho Men'Eki Gakkai Kaishi = Japanese Journal of Clinical Immunology|November 1, 2008
[Cancer antigen WT1-targeting treatment for the malignancies]Yoshihiro Oka, Ichiro Kawase
Immunotherapy|September 30, 2010
WT1 peptide vaccine, one of the most promising cancer vaccines: its present status and the future prospectsYoshihiro Oka, Haruo Sugiyama
Tanpakushitsu Kakusan Koso. Protein, Nucleic Acid, Enzyme|August 23, 2003
[Cancer immunotherapy targeting WT1 product which overexpressess in various kinds of malignant neoplasms]Yoshihiro Oka, Akihiro Tsuboi, Haruo Sugiyama
Expert Review of Hematology|March 19, 2019
What should we tackle next in acute myeloid leukemia? Wilms tumor gene 1 vaccine therapy would be a promising and versatile strategy for acute myeloid leukemiaJun Nakata, Yusuke Oji, Yoshihiro Oka, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|September 17, 2002
[Cellular and humoral immune responses against WT1 products overexpressed in hematopoietic malignancies]Yoshihiro Oka, Akihiro Tsuboi, Yusuke Oji, et al.
Current Opinion in Immunology|May 27, 2008
WT1 peptide vaccine for the treatment of cancerYoshihiro Oka, Akihiro Tsuboi, Yusuke Oji, et al.
Materials (Basel, Switzerland)|January 21, 2023
Dispersion of Long and Isolated Single-Wall Carbon Nanotubes by Using a Hydrodynamic Cavitation MethodShunjiro Fujii, Shin-Ichi Honda, Yoshihiro Oka, et al.
Haematologica|March 17, 2004
Allogeneic bone marrow transplantation with non-T-cell-depleted marrow from two HLA-antigen-mismatched related donorsHiroyasu Ogawa, Kazuhiro Ikegame, Manabu Kawakami, et al.
Pediatric Blood & Cancer|June 29, 2010
WT1 peptide immunotherapy for cancer in children and young adultsYoshiko Hashii, Emiko Sato, Hideaki Ohta, et al.
Brain and Nerve = Shinkei Kenkyu No Shinpo|July 22, 2009
[Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors]Naoya Hashimoto, Akihiro Tsuboi, Yasuyoshi Chiba, et al.
Pageof 14